Introduction
Intrauterine gene transfer allows production of specific gene products before birth, and may be suitable for treatment of certain genetic diseases with considerable perinatal morbidity and mortality such as deficiencies of adenosine deaminase, ornithine carbamoyl transferase, and protein C. Defects in structural proteins such as dystrophin and cystic fibrosis transmembrane receptor (CFTR) may also be treated by intrauterine gene transfer. If proper control of transgene expression can be employed, gene transfer into stem cells in developing embryonic tissues may offer advantages for treating these diseases. Intrauterine gene transfer during an immunoprivileged stage of development may establish tolerance to transgene product(s), thus allowing their persistent production.
Several reports to date have described the feasibility of various approaches of intrauterine gene transfer. Recombinant retroviruses were shown to transduce cells after direct injections into mouse embryos.
1,2 Douar et al 3 showed that while direct intra-amniotic injection of retroviruses carrying bacterial ␤-galactosidase (␤-gal) reporter gene did not result in gene transfer, implantation of retrovirus-producing cells into the amniotic cavity was successful in inducing effective gene transfer in mice. However, intra-amniotic injections of adenoviral vectors carrying ␤-gal gene resulted in ␤-gal expression in the skin, buccal/nasal cavity and pulmonary epithelium of embryos in mice. 3 Direct introduction of ␤-gal adenoviral vectors into the trachea of fetal lambs also resulted in effective ␤-gal transfer to the tracheal, bronchial and distal pulmonary epithelium. 4 Interestingly, tail vein injections of DNA-liposome conjugates into the circulation of pregnant mice were shown to result in ␤-gal expression in the embryos, suggesting clearance of the placental barrier by conjugates. 5 Larson et al 6 reported reversal of the cystic fibrosis phenotype upon intrauterine delivery of CFTR to the cystic fibrosis knockout mice via adenoviral vector. More recently, Porada et al 7 reported that after direct injection of replication-deficient retroviral vectors carrying a neomycin resistance gene (Neo r ) into preimmune sheep fetuses, expression of the Neo r gene was detected even after they were grown into 5-year-old adults.
Together, these observations indicated the potential of intrauterine gene transfer to be developed into a durable therapeutic modality for treating certain genetic diseases with perinatal mortality. However, no systematic investigation has been carried out to date to test its durability in relation to gene delivery vectors, doses, and the gestational stage of the embryos.
In the present article, we describe intrauterine gene transfer in mice utilizing adenoviral and retroviral vectors carrying the ␤-gal gene. Developmental stagespecific gene transfer into the heart or liver by utilizing adenoviral vector, and evidence for stable transgene integration in the heart and liver is described. We also report stable gene transfer into the heart by retrovirus-mediated gene transfer.
Results
Adenovirus-mediated gene transfer Embryos injected with adenovirus showed distinct patterns of ␤-gal gene expression depending on the day of gestational stage (Table 1) . Injections of AdCMVntLacZ (2 × 10 6 p.f.u. per embryo) on day 9.5 post coitum (p.c.) resulted in high level ␤-gal expression in the heart as analyzed on day 13.5 p.c. (Figure 1b) . Control embryos injected with PBS showed no significant staining ( Figure  1a) . Some embryos showed ␤-gal expression mostly in the heart with little expression in other tissues, while others expressed ␤-gal not only in the heart but also in the vasculature, mainly in the umbilical cord and the cephalic large vessels. ␤-Gal activity was predominantly found in the endocardium, atrioventricular cushion, and the endothelium of vasculature (Figure 2a, b) . The choroid plexus showed significant levels of ␤-gal activity, accounting for most of the X-gal staining in the hindbrain (Figure 2c ). No ␤-gal-positive cells were observed in the liver ( Figure 2d ) and lungs (data not shown). AdCMVntLacZ injected on day 9.5 p.c. with increasing titers (5 × 10 6 , 5 × 10
7
, and 1 × 10 9 p.f.u. per embryo) resulted in similar ␤-gal expression with increasing intensity in X-gal staining as the titer increased (data not shown). Embryos injected with the highest titer adenovirus preparation (1 × 10 9 p.f.u. per embryo) showed ␤-gal gene expression in a small number of liver cells, as well as in other additional tissues, particularly in the skin (data not shown). Embryos injected with the lowest titer adenovirus preparation (5 × 10 5 p.f.u. per embryo) showed no detectable ␤-gal expression at any gestational time-point analyzed. Analysis of fetuses on day 18.5 p.c. did not show any significant ␤-gal activity (n = 6) (data not shown).
Embryos injected with AdCMVntLacZ (1 × 10 8 p.f.u. per embryo) on day 11.5 p.c. showed high level ␤-gal expression in the liver as analyzed on day 13.5 p.c. (Figure 1d ). Control embryos injected with PBS did not show any significant staining (Figure 1c ). ␤-Gal-expressing cells were more concentrated in the anterior and flanking regions, although ␤-gal-positive cells were found throughout the liver parenchyma ( Figure 2h ). Transgene expression in the heart was greatly decreased from the level observed in embryos injected on day 9.5 p.c., and was observed mostly in the outflow tract and atria. ␤-Gal-expressing cells were found in the endocardium, myocardium and the epicardium of ventricles (Figure 2e) , contrasting with the predominantly endocardial expression observed after day 9.5 p.c. injections. Caudal vascular structures also showed ␤-gal expression in addition to the cephalic vessels and umbilical cord (Figures 1d and 2f ). Vascular expression was apparently detected only in embryos which showed cardiac ␤-gal activity. The chorioid plexus had high levels of ␤-gal activity (Figure 2g ␤-gal activity in the skin, oral/nasal cavity and liver of five of 18 viable fetuses as analyzed on day 18.5 p.c. (data not shown). There was no detectable ␤-gal expression in the heart.
Persistence of transgene expression upon adenovirusmediated gene transfer Persistence of ␤-gal expression was detected in cardiomyocytes (Figure 3a , b) in two of six, and in hepatocytes (Figure 3c , d) in one of four 2-month-old adult animals injected with AdCMVntLacZ on day 9.5 p.c. or day 11.5 p.c., respectively. ␤-Gal-positive cells were found in clusters, indicating that they were clonally derived from cells which stably integrated the ␤-gal transgene. This pattern of expression suggests that not only retrovirus-mediated, but adenovirus-mediated gene transfer may result in stable chromosomal integration in utero, although at a low efficiency. There was no detectable ␤-gal expression in the brain of the adult animals analyzed, including the ones which showed ␤-gal expression in the heart or liver.
Effect of different promoters of adenoviral vectors on transgene expression
Intraplacental microinjections of adenoviral vector with the RSV promoter, AdRSVntLacZ, on day 9.5 p.c. (5 × 10 7 p.f.u. per embryo) resulted in no significant ␤-gal expression in various tissues, except a low level activity at the base of the heart. No detectable expression was observed in vasculature. Injections on day 11.5 p.c. (2.5 × 10 8 p.f.u. per embryo) resulted in significant activity in liver, hindbrain and skin, similar to the pattern observed with an equivalent dose of AdCMVntLacZ injections on day 11.5 p.c. as described above (Table 1) .
Immunostaining analysis of integrin ␤ 3 subunit Immunostaining of day 9.5 p.c. embryos with monoclonal anti-mouse-CD61 (integrin ␤ 3 subunit) antibody showed the presence of integrin ␤ 3 subunit in the developing heart, while the region caudal to the heart, where the hepatic primordium is located, 8 did not show any detectable signal (Figure 4a , b). However, significant integrin ␤ 3 subunit immunostaining was found in the liver of day 11.5 p.c. embryos, with a non-uniform punctated pattern (Figure 4d , e). Some cells showed high expression, while others showed no or only low level expression. Expression of integrin ␤ 3 subunit in the heart was substantially decreased from the level observed on day 9.5 p.c. Anti-human protein C monoclonal antibody (negative control) did not show any significant immunostaining in either day 9.5 p.c. or day 11.5 p.c. embryos (Figure 4c , f).
Retrovirus-mediated gene transfer ␤-Gal expression was observed in the liver of day 13.5 p.c. embryos after intraplacental microinjections of ␤-gal retroviral vector LZRSLacZ (9 × 10 3 c.f.u. per embryo) with polybrene on either day 9.5 p.c. or day 11.5 p.c. (Table 1) . ␤-Gal gene was expressed in one to five liver cell foci of these embryos (data not shown). No detectable ␤-gal expression, however, was observed in 18 viable fetuses injected on either day 9.5 or 11.5 p.c. and analyzed on day 18.5 p.c., while analysis of 2-month-old adult animals showed multiple cell foci expressing ␤-gal in the myocardium of one of seven animals after virus injection on day 9.5 p.c. (Figure 5 a, b). Although the frequency was low, ␤-gal expression in these cell foci indicated stable integration of the transgene and subsequent clonal expansion of retrovirally transduced progenitor cells. There was no detectable ␤-gal expression in the embryos injected with the virus without polybrene at any timepoint of analysis (n = 101) (data not shown).
Gene transfer to pregnant dams and abortion rates Liver tissues of the pregnant dams which were subjected to intraplacental injections of AdCMVntLacZ or AdRSVntLacZ showed ␤-gal activity correlating with the viral titer used. As analyzed on day 13.5 p.c., animals which received the highest titer adenovirus (2 × 10 12 p.f.u./ml) showed high ␤-gal activity in the liver ( Figure  6c ) compared with the PBS injected control animals ( Figure 6a ). However, none of the animals had any detectable ␤-gal gene expression in the heart (Figure 6b, d ). Liver and heart tissues collected from pregnant dams injected with retrovirus on day 9.5 or day 11.5 p.c. did not show any ␤-gal activity as analyzed on days 13.5 or 18. In Figure 7 , survival rates for PBS, adenovirus and retrovirus injected embryos as analyzed on day 13.5 p.c. are presented. Approximately 70% of injected embryos survived regardless of test samples injected.
c. (a-d) and day 11.5 p.c. (e-h). Embryos were stained with X-gal and cryosectioned at 10 m intervals for (a-d), and GMA embedded and sectioned at 4 m intervals for (e-h

Discussion
In the present studies, we systematically investigated the intraplacental microinjection of recombinant adenoviral and retroviral vectors in mice. Initial testing of intraplacental microinjection with India ink showed that at day 9.5 p.c., the embryonic circulatory system is sufficiently developed to be utilized in systemic delivery of viral vectors to various target tissues and organs, agreeing with the literature. 8 As expected, adenoviral vector injection resulted in gene transfer in various tissues including vasculature and brain (Figure 2) . Unexpectedly, however, adenovirusmediated gene transfer on day 9.5 p.c. and day 11.5 p.c. showed distinct differences in patterns of ␤-gal gene expression in the heart and liver. ␤-Gal gene transfer was distinctly high in the heart after adenoviral injection on day 9.5 p.c., but substantially decreased as embryogenesis progressed to day 11.5 p.c (Figure 1 ). In adults, adenovirus-mediated gene transfer into the heart was non-detectable as shown by negative ␤-gal expression in the injected pregnant dams (Figure 6 ), indicating that adenoviral transduction of heart cells decreases as the developing mouse matures to later stages. In contrast, transduction of the liver was minimal on day 9.5 p.c., probably because the liver is just beginning to develop. 8 The drastic increase in transduction observed upon adenovirus injection on day 11.5 p.c. indicates that the embryonic liver has reached a stage at which it is readily transduced by adenoviral vectors. This observation was consistent regardless of low and high viral titers used (2 × 10 6 and 1 × 10 9 p.f.u. per embryo). Baldwin et al 9 reported that upon exposure to adenoviral vector with CMV promoter, cultured early gestation murine embryos (7.25 days p.c.) expressed ␤-gal in the heart and the vasculature. ␤-Gal gene expression was limited to the endocardial and endothelial cells. Our observations on embryos injected with AdCMVntLacZ on day 9.5 p.c. is consistent with that of Baldwin et als. Predominant endothelial ␤-gal expression upon injection on day 9.5 is presumably due to the high accessibility of endothelium to the injected adenovirus at this stage of development as well as the susceptibility of endothelium to adenoviral transduction. 9 However, the persistence of ␤-gal expression in adult cardiomyofibers near the apex of the heart (Figure 3a, b) , which are presumably not derived from mesenchymal differentiation of atrioventricular endocardial cells, suggests that mesenchymal cells may also have been transduced by injected adenovirus on day 9.5 p.c. This observation is again consistent with data reported by Baldwin et al 9 with the day 7.25 p.c. embryos transduced with a ␤-gal adenoviral vector with RSV promoter in culture. These studies showed that ␤-gal expression was in the myocardium, and not in the endocardium and endothelium, suggesting that expression of the ␤-gal gene delivered by adenoviral vector is promoter-dependent and tissue-specific. 9 However, our studies demonstrated that the activity of CMV promoter was not limited to endocardial and endothelial cells upon injections of AdCMVntLacZ on day 11.5 of gestation, as ␤-gal expression in the myocardium and pericardium, in addition to endocardium, was clearly evident on day 13.5 p.c (Figure 2e ). These findings indicate that CMV promoter is active in these cells at this particular developmental stage. In our studies, transgene expression in the heart after injections of ␤-gal adenoviral vector with RSV promoter (AdRSVntLacZ) on day 9.5 p.c. was significantly lower compared with AdCMVntLacZ under comparable conditions, whereas ␤-gal expression in the liver was similar for both adenoviral vectors upon injections on day 11.5 p.c. Adenoviral transduction of heart and liver in mice by intraplacental injections was also reported by Woo et al. 10 Injections on days 12-13 p.c. with adenoviral vector with an RSV promoter and either ␤-gal or luciferase reporter gene resulted in higher transgene expression in the heart compared with the liver, whereas total transgene activity was higher in the liver before normalization for tissue mass. 10 In our studies, high level expression of ␤-gal in the liver after injection of AdCMVntLacZ on day 11.5 p.c. 
c. (a and b) and day 11.5 p.c. (d and e) embryos for ␤ 3 integrin subunit (CD61). (a) and (d) H&E staining of cryosections of days 9.5 and 11.5 p.c. embryos, respectively (h: heart; lp: region of liver primordium; l: liver; i: intestine; lu: lung). (b) and (e) Immunostaining of cryosections adjacent to those of (a) and (d) with anti-mouse CD61 monoclonal antibody, respectively. (c) and (f) Immunostaining of adjacent cryosections of (a) and (d), respectively, with anti-human protein C monoclonal antibody. Integrin ␤ 3 subunit expression is seen as green color in the heart of day 9.5 p.c. embryo (b), and in the liver of day 11.5 p.c. embryo (e). Expression of integrin ␤ 3 subunit in heart on day 11.5 p.c. is significantly lower compared with day 9.5 p.c. Low level ␤ 3 integrin subunit immunostaining is seen in intestines, while lungs do not show any significant expression.
was observed in clear contrast to the minimal ␤-gal expression after day 9.5 p.c. injection. Together, these results suggest that substantial differences are present in mouse development between day 9.5 p.c. and day 11.5 p.c. which confer differential adenoviral transduction of the heart and liver. This is the first demonstration of such developmental stage-specific gene transfer by adenoviral vector.
It is known that the adult heart is difficult to transduce with adenoviral vectors, thus requiring local delivery of the viral suspension via catheter.
11 This is consistent with our findings that the hearts of pregnant dams injected with adenoviral vectors are poorly transduced ( Figure  6d) .
The gestational stage-specific tropism of the adenoviral transduction observed in the present studies may be due to the difference in maturity of the transduction mechanisms involved such as availability of receptors, and also to the accessibility of target tissues via the circulatory system at specific stages of development. The cardiovascular system is one of the first organ systems to develop. 8 By day 9.5 p.c., the heart is already well defined and contracting, while the liver is still at an early developmental stage, and no significant vascularization is seen in the liver primordium. During the following 2 days, liver mass drastically increases and it starts to function as a hematopoietic organ. 8 Since we detected ␤-gal gene transfer in the liver, although at a lower efficiency, after retrovirus injections on day 9.5 p.c. in addition to day 11.5 p.c., the vascular system in the developing liver may already be partially formed on day 9.5 p.c. to some extent, thus enabling low level viral vector delivery. This is also consistent with our observation that when a high titer of ␤-gal adenovirus (1 × 10 9 p.f.u. per embryo) was used for injection on day 9.5 p.c., a small number of ␤-gal-expressing cells could be detected in the liver. Together, these results suggest that liver progenitor cells are already present on day 9.5 of development, but they are more resistant or inefficiently accessible to adenoviral transduction than liver cells at later stages. This is presumably due to a combination of a premature vascular system and absence or low level availability of cell surface molecules required for efficient adenoviral transduction.
Figure 6 Liver and heart tissues of pregnant dams harvested 4 days after intraplacental microinjections. Tissues were stained with X-gal, cleared with BBBA solution, and photographed under a dissection microscope (see Materials and methods). (a) and (b) Liver and heart tissues of an animal injected with PBS, respectively. (c) and (d) Liver and heart tissues of an animal injected with AdCMVntLacZ (2 × 10 12 p.f.u./ml), respectively. The liver tissue of the animal injected with ␤-gal adenovirus (c) shows intense X-gal staining compared with the control (a), while no detectable staining is observed in the heart (d).
Infection of cells with adenovirus serotypes 2 or 5 requires the presence of Coxsackie B/adenovirus receptor (CAR) for binding, 12, 13 and also ␣ v integrins, 14 such as integrins ␣ v ␤ 3 , or ␣ v ␤ 5 , for internalization of viral particles. 15, 16 Integrins are heterodimeric cell adhesion molecules, and are differentially expressed during murine embryogenesis 17 and cardiac development. 18 The developmental stage-specific switch of adenoviral tropism may be due to differential expression of CAR and/or these integrins during development. Almost exclusive cardiac expression of integrin ␤ 3 subunit on day 9.5 p.c. followed by a dramatic decrease in its expression in heart contrasts with high level expression in liver on day 11.5 p.c., thus strongly supporting our hypothesis (Figure 4 ). These observations warrant further investigation into the developmental stage-specific expression of CAR, ␣ v , ␤ 1 and ␤ 5 subunits of integrins, as well as blocking studies with coinjection of adenoviral vectors with specific antibodies toward these molecules implicated in adenoviral transduction.
Persistent ␤-gal expression after intrauterine gene transfer in multiple cell foci in both heart and liver tissues of 2-month-old adult animals indicates stable transgene integration into the host cell genome, although at a low efficiency (Figure 3) . The appearance of clusters of ␤-galpositive cells suggests that they originated from a few progenitor cells that stably integrated adenoviral transgene. Previously we reported persistent long-term survival of adenovirally transduced human factor IX gene in the liver of not only immune-deficient, but immunecompetent adult mice. 19 Persistence of ␤-gal expression 1692 in mice upon adenoviral gene delivery in the neonatal period was also described. 20 In these cases persistence of the adenovirally delivered genes is primarily due to extrachromosomal survival of the adenoviral transgene, and the extent of contribution of the stably integrated genome, if any, is not known.
Amphotropic retrovirus-mediated gene transfer via intraplacental microinjection of the ␤-gal gene resulted in low frequency ␤-gal gene transfer only in the presence of polybrene. This may be due to the relatively low titer retroviral vector used (1.8 × 10 7 c.f.u./ml), although it was the highest we could obtain at the present time. It may be possible to increase the gene transfer efficiency by using a higher titer retrovirus preparation. Interestingly, mouse fetal liver cells were reported to lack functional amphotropic retroviral receptors and could be transduced only with ecotropic retrovirus, regardless of the viral titer used. 21 A similar phenomenon was also reported for rat fetal liver cells. 22 Casal et al, 23 however, reported that mouse fetal liver cells can be transduced in vitro with amphotropic retroviral vectors, presumably due to a high local retroviral concentration used as these cells were co-cultivated with retrovirus-producing cells in a dual-chambered system. Our observations in vivo are consistent with the latter report. Our experiments demonstrate that intraplacental injections of amphotropic ␤-gal retroviral vector on day 9.5 p.c. and day 11.5 p.c. can result in transduction of liver cells as examined on day 13.5 p.c. It is worthwhile to mention that any significant retroviral transduction occurs only in the presence of polybrene, which is consistent with its augmenting effects on retroviral transduction in vitro and in vivo. The persistence of ␤-gal gene expression in the heart muscle upon delivery of ␤-gal retrovirus on day 9.5 p.c. indicates that murine cardiac precursor cells may also be transduced, suggesting the presence of amphotropic receptor on these cells. Long-term expression of the ␤-gal transgene in multiple clustered cell foci indicates that stable genomic integration of the transgene has occurred ( Figure 5 ).
We also tested intraplacental microinjections of ␤-gal adeno-associated virus (AAV) on day 9.5 p.c., but no detectable gene transfer was observed at any time-point analyzed (unpublished data). Lack of transgene expression was not unexpected for AAV as analyzed on day 13.5 p.c., because AAV is known to have an initial 1-2 week lag period before showing transgene expression after in vivo delivery. 24 However, fetuses analyzed on day 18.5 p.c. and as adults at 2 months of age also showed no detectable ␤-gal expression, thus suggesting that in spite of using a reasonably high titer of AAV (4.25 × 10 5 IU per embryo), no detectable AAV transduction took place under the conditions used. The AAV titer used efficiently transduced myoblasts in culture (unpublished data). These observations were unexpected because AAV is known to transduce both dividing and non-dividing cells, as reviewed by Rabinowitz and Samulski. 25 Both AAV and adenoviral vectors used in these experiments have similar CMV promoters, and therefore possible CMV promoter inactivation does not explain this phenomenon. Developmental stage-specific mechanisms, such as low level expression of the AAV receptor, may be responsible. The responsible mechanism(s) remains to be determined.
The abortion rates observed after intraplacental microinjections ( Figure 7 ) may represent the collective outcome of physical trauma of the procedure, biological effects of viral vector used, subtle differences in the developmental stage of the recipient embryos, and individual differences among the pregnant dams. Further studies are needed to dissect these variables. Together, these results further support the potential utility of intrauterine gene transfer for treating genetic disorders with perinatal morbidity and mortalitity. However, several critical issues must be rigorously addressed to minimize or totally eliminate potential risks pertinent to this approach before considering human application. For instance, if a recombinant viral gene delivery vector, such as adenovirus is used, immunotolerance established to the vector may possibly permit unchecked subsequent infection by the parent wild-type virus. Development of efficient and safe nonviral gene delivery vector systems may be needed. Another important issue to be addressed is possible germ line gene transfer and its prevention. Further extensive studies into the basic biology involved, particularly using large animal models, are warranted to address these important issues towards developing a safe and durable intrauterine gene transfer method. Mice Timed-pregnant CD-1 mice were obtained from Charles River (Wilmington, MA, USA), and were housed in the specific pathogen-free facility of the Unit of Laboratory Animal Medicine of this campus. All animal experiments were carried out according to the institutional guidelines for animal use. Animals injected with viral vectors and their offspring were kept in biohazard isolation modules until killed for analyses.
Materials and methods
Recombinant viral vectors
Intraplacental microinjection
Intraplacental microinjection was performed as previously described 26, 27 with minor modifications. The procedure was first tested by injecting India ink into embryos at 9.25-9.75 days p.c. (day 9.5 p.c.) and 11.25-11.75 days p.c. (day 11.5 p.c.). Briefly, pregnant dams were anesthetized with tribromoethanol (14 l/g; Aldrich, Milwaukee, WI, USA) 27 and a medial surgical incision was made on the lower abdomen. After exposing the uterus, aliquots (500 nl) of India ink were injected with a glass needle (36 m diameter opening) into the placentas of day 9.5 p.c. and day 11.5 p.c. embryos. Needles were guided into position with a micromani-pulator (Leitz, Deerfield, IL, USA) under a stereoscopic microscope (SMZ-U; Nikon, Melville, NY, USA) at a magnification of 10-20×. A calibrated micrometer syringe was used to deliver precise volumes into target tissue. After 10 min, animals were killed by CO 2 inhalation, and embryos were collected and photographed. For intrauterine gene transfer experiments, 500 nl aliquots of viral suspension or PBS (10 mm sodium phosphate buffer, 27 mm KCl, 137 mm NaCl, pH 7.4; all chemicals were obtained from Sigma, St Louis, MO, USA unless specified otherwise) were injected into day 9.5 p.c and day 11.5 p.c. embryos, and 1 l aliquots were injected into 14.25-14.75 day p.c. (day 14.5 p.c.) embryos with the same method as for India ink injections. Retroviral vector was injected with or without polybrene (10 g/ml). After the surgical wound was sutured and the skin was stapled, animals were allowed to recover on a warming pad.
Analysis of ␤-gal expression Pregnant dams were killed at day 13.5 p.c. or day 18.5 p.c. by cervical dislocation following brief anesthesia with CO 2 , and mid-gestation embryos and perinatal fetuses were collected. Unless otherwise stated, livers and hearts were also collected from all dams killed. Embryo and tissue specimens were rinsed with PBS and fixed in ice-cold PBS solution containing 4% formaldehyde, 0.2% glutaraldehyde and 0.1% NP40 for 20 min with moderate shaking. One limb on each side of the fetuses was amputated after 5 min in the fixative to facilitate adequate solution penetration. Specimens were then washed twice with PBS for 20 min, and incubated overnight in 2 mm X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactoside; GibcoBRL, Grand Island, NY, USA) solution (pH 7.4) at 30°C. 28 Some embryos were subjected to histochemical analyses with cryosectioning and subsequent X-gal staining according to the standard methods. 28 Adult animals (2 months of age) were anesthetized with tribromoethanol 27 and the left ventricle was cannulated with a 25 G catheter. A small incision was made on the right atrium and the animal was first perfused with PBS (37°C, pH 7.4) at a rate of 1 ml/min, followed by perfusion with ice-cold fixative as described above. A final perfusion with PBS was done after fixation was completed. Efficacy of perfusion was judged by successful blanching of the liver and eyes after the initial PBS perfusion, and obvious stiffening of the whole body after fixation. The viscera were dissected en bloc including the heart, lungs, liver, spleen and kidneys. Stomach and intestines were not subjected to ␤-gal analysis because of the high ␤-gal-like background activity present in these tissues. Organs were placed in the fixative for an additional 45 min, rinsed and stained as described above for embryos.
Clearing of the embryos was done as described. 29 Briefly, specimens were dehydrated in 100% methanol for 2 days after completion of ␤-gal staining, followed by soaking in a mixture of benzyl benzoate:benzyl alcohol (BBBA) (2:1, v/v). After sufficient clearing, specimens were analyzed under a dissection microscope (SMZ-10; Nikon) and photographed. Adult animal tissues were similarly cleared. For thorough analysis of the day 18.5 p.c. fetuses and adult tissues, further dissection of the specimens was required. Selected cleared embryo and tissue specimens were then de-cleared by serial incubation in 100, 75 and 50% methanol in PBS, and PBS in the order according to our recent modifications. 30 Specimens were then embedded in glycolmethacrylate (GMA) with a JB-4 kit (Polysciences, Warrington, PA, USA) according to the manufacturer's instructions, and sectioned at 4 m intervals. Tissue sections were stained with half-strength Gill's hematoxylin and eosine-phloxine stain (H&E).
Immunostaining of embryos Pregnant mice were killed by cervical dislocation after brief CO 2 anesthesia. Embryos of day 9.5 p.c. and day 11.5 p.c. were harvested. Embryos were immediately rinsed in PBS, embedded in OCT compound (Miles, Elkhart, IN, USA), and snap frozen in 2-methylbutane cooled on liquid nitrogen. Cryosections were taken at 10 m intervals, fixed in acetone at −20°C for 18 min, and air dried. After blocking with 3% bovine serum albumin (BSA; Boehringer Mannheim, Indianapolis, IN, USA) in PBS for 1 h, sections were incubated for 90 min with FITC-labeled anti-mouse CD61 monoclonal antibody (Pharmingen, San Diego, CA, USA) in PBS containing 1% BSA (1:500 dilution). A non-labeled anti-human protein C monoclonal antibody (Celsus Laboratories, Cincinnati, OH, USA) was used as a negative control, under the same conditions. Sections were rinsed with PBS, and cover slips mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA). Specimens were then examined and recorded with a fluorescence microscope (BX 40; Olympus, Lake Success, NY, USA) equipped with a CCD camera (Diagnostic Instruments, Sterling Heights, MI, USA). Cryosections adjacent to the slides used for immunostaining were subjected to H&E stain, and were used to correlate immunostaining patterns with tissue morphology. The specificity of the antibody used for the integrin ␤ 3 subunit was demonstrated by strong immunostaining with megakaryocytes of adult mouse bone marrow, while no detectable immunostaining of megakaryocytes was observed with anti-human protein C monoclonal antibody used as a negative control.
